Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners

This year's Aspire Higher scholarships are awarded to six students who have been affected by dermatologic conditions. LAVAL, QC, Aug. 27, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its dermatology business, Ortho Dermatologics, today announced the recipients of its 2026 Aspire Higher Scholarship Program.

PRNewsWire • Aug 27, 2026

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results. “Helping people see better to live better starts with tackling the challenges patients still face every day,” said Bausch + Lomb CEO Brent Saunders. “These results suppor.

Business Wire • Aug 24, 2026

Can Bausch (BHC) Run Higher on Rising Earnings Estimates?

Bausch Health (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Investment Research • Aug 21, 2026

Bausch (BHC) Upgraded to Buy: Here's What You Should Know

Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Aug 21, 2026

Bausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine

Bausch + Lomb is positioned as a turnaround and deleveraging opportunity, benefiting from a shift toward higher-margin products and expanding global distribution. Q2 2026 results showed broad-based revenue growth (9% YoY), significant margin expansion, and strong operating cash flow, supporting an optimistic outlook. Premium intraocular lenses and branded pharmaceuticals are driving faster growth, improving mix, and enabling margin and EBITDA expansion without unsustainable revenue acceleration.

Seeking Alpha • Aug 20, 2026

Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners

For the Seventh Consecutive Year, 10 Students with Gastrointestinal Disease  Will Each Receive a $10,000 Scholarship LAVAL, QC, Aug. 17, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the recipients of its 2026 Salix Gastrointestinal Health Scholars Program. For the seventh year, Bausch Health is proud to award 10 deserving students living with a GI disease $10,000 each to further their higher education.

PRNewsWire • Aug 17, 2026

Bausch Health: Q2 Beat And Cheap, But Debt Overhang Remains Substantial

Bausch Health Companies Inc. has surged 40% post-Q2 on strong results and raised FY2026 guidance, but balance sheet risks remain paramount. BHC delivered Q2 non-GAAP EPS of $1.26, beating consensus by $0.25, with 13% revenue growth and notable margin and cash flow improvements. Despite operational momentum, BHC's $15B long-term debt and $800M H1 interest expense drive speculative credit ratings and analyst skepticism.

Seeking Alpha • Aug 12, 2026

Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Aug 11, 2026

Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month

Investors were cheered by the beat-and-raise second quarter. The company also had good news to report from its Canadian subsdiary.

The Motley Fool • Aug 10, 2026

Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board

LAVAL, QC, Aug. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb Corporation (NYSE: BLCO)(TSX: BLCO), a subsidiary of Bausch Health Companies Inc., effective August 5, 2026.

PRNewsWire • Aug 6, 2026